黎族与汉族系统性红斑狼疮患者的主要临床特征

doi:10.19723/j.issn.1671-167X.2025.06.031

摘要/Abstract

关键词: 系统性红斑狼疮, 黎族, 汉族, 临床表现, 实验室检查

中图分类号:

R593.24

王小梦, 曾晓君, 李娟. 黎族与汉族系统性红斑狼疮患者的主要临床特征[J]. 北京大学学报（医学版）, 2025, 57(6): 1213-1218.

王小梦, 曾晓君, 李娟. [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1213-1218.

图/表 3

表1

表2

首次因SLE住院的汉族与黎族患者实验室检查结果"

Items	Han Chinese patients	Li ethnic patients	Statistic	P
Blood routine examination
Lymphocyte count/(×10⁹/L)	1.15 (0.72, 1.74)	1.12 (0.62, 2.00)	U=13 977.500	0.179
Neutrophil count/(×10⁹/L)	3.50 (2.30, 5.69)	3.44 (2.47, 6.59)	U=32 527.500	0.263
Low white blood cell (< 4×10⁹/L)	280/1 060 (26.4)	21/67 (31.3)	χ²=3.518	0.172
Low hemoglobin (< 120 g/L)	766/1 060 (72.3)	54/67 (80.6)	χ²=2.583	0.275
Low platelet (< 100×10⁹/L)	140/1 060 (13.2)	7/67 (10.4)	χ²=0.573	0.751
hsCRP/(mg/L)	3.16 (1.01, 10.70)	3.60 (0.06, 14.36)	U=21 425.500	0.356
ESR/(mm/h)	44.00 (20.25, 81.00)	46.50±58.75	U=21 227.500	0.490
Lupus nephritis	429/916 (46.8)	29/57 (50.9)	χ²=1.241	0.534
24-UTP/(mg/24 h)	586.85 (211.05, 2 261.20)	860.71 (306.23, 2 886.63)	U=9 184.500	0.092
Blood biochemistry
Creatinine/(μmol/L)	67.20 (52.40, 94.98)	60.25 (46.50, 98.43)	U=33 395.500	0.801
BUN/(mmol/L)	5.40 (3.91, 8.92)	4.88 (3.19, 8.73)	U=30 527.500	0.275
ALT/(U/L)	22.73 (16.00, 34.93)	23.37 (16.00, 28.67)	U=31 302.500	0.190
AST/(U/L)	25.00 (17.00, 38.00)	21.00 (14.50, 31.50)	U=34 528.000	0.965
ALP/(U/L)	67.50 (53.00, 86.75)	57.50 (38.25, 78.50)	U=28 690.000	0.027
γ-GGT/(U/L)	24.00 (14.00, 46.00)	20.71 (14.00, 40.24)	U=30 873.000	0.194
SLE-related antibodies
ANA	893/936 (95.4)	63/63 (1)	χ²=3.072	0.215
Anti-dsDNA	338/901 (37.5)	19/63 (30.2)	χ²=3.062	0.216
Anti-SSA	406/850 (47.8)	30/61 (49.2)	χ²=0.046	0.831
Anti-SSB	98/850 (11.5)	3/61 (4.9)	χ²=2.524	0.112
Anti-Ro-52	324/850 (38.1)	18/61 (29.5)	χ²=1.799	0.180
Anti-U1-RNP/Sm	301/850 (35.4)	25/60 (41.7)	χ²=0.954	0.329
Anti-Sm	150/850 (17.6)	19/61 (31.1)	χ²=6.866	0.009
Anti-histone	143/850 (16.8)	11/60 (18.3)	χ²=0.091	0.763
Anti-nucleosome	173/850 (20.4)	13/60 (21.7)	χ²=0.059	0.807
Anti-ribosomal P protein	174/848 (20.5)	12/59 (20.3)	χ²=0.001	0.974
LA	34/145 (23.4)	1/2 (50)	χ²=0.767	0.381
aCL	52/468 (11.1)	0/32 (0)	χ²=3.968	0.046
Anti-β2GPⅠ	108/476 (22.7)	4/33 (12.1)	χ²=2.008	0.156
P-ANCA	263/652 (40.3)	20/49 (40.8)	χ²=0.004	0.947
C-ANCA	6/652 (0.9)	0/49 (0)	χ²=0.455	0.500
Anti-MPO	48/528 (9.1)	4/38 (10.5)	χ²=0.088	0.767
Anti-PR3	2/528 (0.4)	0/38 (0)	χ²=0.145	0.704
Low C3	650/1 060 (61.3)	43/67 (64.2)	χ²=1.812	0.404
Low C4	382/1 060 (36.0)	30/67 (44.8)	χ²=2.651	0.266
SLEDAI-2K	7.00 (4.00, 9.00)	6.00 (4.00, 10.00)	U=33 260.000	0.402

表2

表3

参考文献 20

1	Rees F , Doherty M , Grainge MJ , et al. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies[J]. Rheumatology, 2017, 56 (11): 1945- 1961. doi: 10.1093/rheumatology/kex260
2	Molineros JE , Yang W , Zhou XJ , et al. Confirmation of five novel susceptibility loci for systemic lupus erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci[J]. Hum Mol Genet, 2017, 26 (6): 1205- 1216.
3	Deng GM , Tsokos GC . Pathogenesis and targeted treatment of skin injury in SLE[J]. Nat Rev Rheumatol, 2015, 11 (11): 663- 669. doi: 10.1038/nrrheum.2015.106
4	Li M , Zhao Y , Zhang Z , et al. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Rheumatol Immunol Res, 2020, 1 (1): 5- 23. doi: 10.2478/rir-2020-0009
5	Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40 (9): 1725.
6	Bombardier C , Gladman DD , Urowitz MB , et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE[J]. Arthritis Rheum, 1992, 35 (6): 630- 640. doi: 10.1002/art.1780350606
7	Lewis MJ , Jawad AS . The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus[J]. Rheumatology, 2017, 56 (Suppl 1): i67- i77.
8	史曼曼, 王语欣, 马毓华, 等. 系统性红斑狼疮的遗传学研究进展[J]. 内科理论与实践, 2022, 17 (3): 267- 272.
9	Metry AM , Al Salmi I , Al Balushi F , et al. Systemic lupus erythematosus: Symptoms and signs at initial presentations[J]. Antiinflamm Antiallergy Agents Med Chem, 2019, 18 (2): 142- 150. doi: 10.2174/1871523018666181128161828
10	Al Dhanhani AM , Agarwal M , Othman YS , et al. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE[J]. Lupus, 2017, 26 (6): 664- 669. doi: 10.1177/0961203316678677
11	AlSaleh J , Jassim V , ElSayed M , et al. Clinical and immunological manifestations in 151 SLE patients living in Dubai[J]. Lupus, 2008, 17 (1): 62- 66. doi: 10.1177/0961203307084297
12	Alballa SR . Systemic lupus erythematosus in Saudi patients[J]. Clin Rheumatol, 1995, 14 (3): 342- 346. doi: 10.1007/BF02208351
13	Hammoudeh M , Al-Momani A , Sarakbi H , et al. Oral manifestations of systemic lupus erythematosus patients in Qatar: A pilot study[J]. Int J Rheumatol, 2018, 2018, 6052326.
14	Petri M , Purvey S , Fang H , et al. Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort[J]. Arthritis Rheum, 2012, 64 (12): 4021- 4028. doi: 10.1002/art.34672
15	Rúa-Figueroa I , López-Longo FJ , Calvo-Alén J , et al. National registry of patients with systemic lupus erythematosus of the Spa-nish Society of Rheumatology: Objectives and methodology[J]. Reumatol Clin, 2014, 10 (1): 17- 24. doi: 10.1016/j.reuma.2013.04.013
16	Nightingale AL , Davidson JE , Molta CT , et al. Presentation of SLE in UK primary care using the Clinical Practice Research Data-link[J]. Lupus Sci Med, 2017, 4 (1): e000172. doi: 10.1136/lupus-2016-000172
17	Yu P , Zhu Q , Chen C , et al. Association between major histocompatibility complex class Ⅰ chain-related gene polymorphisms and susceptibility of systemic lupus erythematosus[J]. Am J Med Sci, 2017, 354 (4): 430- 435. doi: 10.1016/j.amjms.2017.06.003
18	Li M , Wang Y , Zhao J , et al. Chinese SLE treatment and research group (CSTAR) registry 2009-2019: Major clinical cha-racteristics of Chinese patients with systemic lupus erythematosus[J]. Rheumatol Immunol Res, 2021, 2 (1): 43- 47. doi: 10.2478/rir-2021-0001
19	Wang M , Zhang X , Zhang Y , et al. Prevalence and genetic analysis of thalassemia and hemoglobinopathy in different ethnic groups and regions in Hainan Island, southeast China[J]. Front Genet, 2022, 13, 874624. doi: 10.3389/fgene.2022.874624
20	Tao F , Lai Y , Chen J , et al. Prevalence of thalassaemia among childbearing-age Li and Han populations in Hainan Province[J]. Hematology, 2024, 29 (1): 2417524. doi: 10.1080/16078454.2024.2417524

相关文章 15

[1]	李欣艺, 赵金霞, 穆荣. 阿司匹林对系统性红斑狼疮妊娠者结局的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1074-1080.
[2]	王晓林, 郭邵逸, 陈大召, 温锡杰, 华勇, 张亮, 张秦. 全髋关节置换术治疗系统性红斑狼疮继发股骨头缺血性坏死的随访研究[J]. 北京大学学报（医学版）, 2025, 57(6): 1081-1088.
[3]	卫春, 杨月, 赵新菊, 刘栩, 贾园. 系统性红斑狼疮合并自身免疫性郎飞结病1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1174-1179.
[4]	赵凯, 鲁芙爱, 王永福. 中枢神经系统感染模拟神经精神狼疮1例[J]. 北京大学学报（医学版）, 2025, 57(6): 1188-1192.
[5]	王文琼, 侯玉珂, 李春, 张学武. 系统性红斑狼疮患者不良妊娠结局的预测因素[J]. 北京大学学报（医学版）, 2025, 57(3): 599-603.
[6]	王红彦, 李鑫铭, 房柯池, 朱华群, 贾汝琳, 王晶. 系统性红斑狼疮疾病活动度相关特征分析及评估模型的构建[J]. 北京大学学报（医学版）, 2024, 56(6): 1017-1022.
[7]	陈丹丹, 李云, 卢情怡, 相晓红, 孙峰, 李英妮, 赵静, 王红彦, 李春. 育龄期系统性红斑狼疮患者卵巢功能的评价及其影响因素[J]. 北京大学学报（医学版）, 2024, 56(6): 1023-1028.
[8]	王莉, 高超, 任欢欢, 沈艳平, 黄晓玮, 姚鸿, 韩丹丹. 系统性红斑狼疮患者自我管理能力现状及相关因素分析[J]. 北京大学学报（医学版）, 2024, 56(6): 1029-1035.
[9]	柴静, 王钥, 穆荣, 赵金霞. 系统性红斑狼疮累及穹窿柱导致低钠血症1例[J]. 北京大学学报（医学版）, 2024, 56(6): 1115-1118.
[10]	王明霞, 丁菱, 王敏, 邹婵娟, 颜丝语, 梁颖文, 王伟佳, 何善智. 双靶点嵌合抗原受体T细胞治疗系统性红斑狼疮患者停药后安全孕产1例[J]. 北京大学学报（医学版）, 2024, 56(6): 1119-1125.
[11]	武志慧, 胡明智, 赵巧英, 吕凤凤, 张晶莹, 张伟, 王永福, 孙晓林, 王慧. miR-125b-5p修饰脐带间充质干细胞对系统性红斑狼疮的免疫调控机制[J]. 北京大学学报（医学版）, 2024, 56(5): 860-867.
[12]	乔佳佳,田聪,黄晓波,刘军. 肾结石合并系统性红斑狼疮行经皮肾镜碎石取石术的安全性和有效性评估[J]. 北京大学学报（医学版）, 2024, 56(4): 745-749.
[13]	任立敏,赵楚楚,赵义,周惠琼,张莉芸,王友莲,沈凌汛,范文强,李洋,厉小梅,王吉波,程永静,彭嘉婧,赵晓珍,邵苗,李茹. 系统性红斑狼疮低疾病活动度及缓解状况的真实世界研究[J]. 北京大学学报（医学版）, 2024, 56(2): 273-278.
[14]	罗芷筠,吴佳佳,宋优,梅春丽,杜戎. 伴神经精神系统病变的系统性红斑狼疮相关巨噬细胞活化综合征2例[J]. 北京大学学报（医学版）, 2023, 55(6): 1111-1117.
[15]	姚海红,杨帆,唐素玫,张霞,何菁,贾园. 系统性红斑狼疮及成人Still病合并巨噬细胞活化综合征的临床特点及诊断指标[J]. 北京大学学报（医学版）, 2023, 55(6): 966-974.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Items	Han Chinese patients (n=1 060)	Li ethnic patients (n=67)	Statistics	P
Gender (Female)	944 (89.1)	64 (95.5)	χ²=2.109	0.233
Age/years	35.99±16.50	28.42±13.16	t=3.684	＜0.001
Rash	269 (25.4)	24 (35.8)	χ²=3.908	0.142
Joint pain	257 (24.3)	26 (38.8)	χ²=10.036	0.007
Muscle pain	27 (2.5)	0 (0)	χ²=1.776	0.411
Lung involvement	289 (27.3)	20 (29.9)	χ²=0.590	0.745
Renal involvement	424 (40.0)	30 (44.8)	χ²=1.272	0.529
Neuro-psychiatric system involvement	126 (11.0)	6 (9.0)	χ²=8.009	0.018
Leukopenia	261 (24.6)	19 (28.4)	χ²=3.487	0.175
Hemolytic anemia	5 (0.5)	0 (0)	χ²=0.322	0.851
Thrombocytopenia	101 (9.5)	6 (9.0)	χ²=0.129	0.938
Lupus liver involvement	65 (6.1)	5 (7.5)	χ²=0.258	0.879
Pulmonary hypertension	35 (3.3)	1 (1.5)	χ²=0.701	0.704
Thrombotic microangiopathy	7(0.7)	0 (0)	χ²=0.452	0.798
Cardiac involvement	158 (14.9)	6 (9.0)	χ²=1.966	0.374
Digestive system involvement	176 (16.6)	10 (14.9)	χ²=0.327	0.849
Reynold syndrome	33 (3.1)	5 (7.5)	χ²=3.697	0.157
Acute kidney injury	11 (1.0)	2 (3.0)	χ²=2.109	0.348
Chronic kidney disease	50 (4.7)	2 (3.0)	χ²=0.478	0.787
Maintenance hemodialysis	27 (2.5)	1 (1.5)	χ²=0.315	0.854

Items	Han Chinese patients (n=1 060)	Li ethnic patients (n=67)	χ²	P
Thalassemia	20 (1.9)	6 (9.0)	14.006	＜0.001
HT	101 (10.4)	3 (4.5)	2.022	0.364
RA	35 (3.3)	0 (0)	2.317	0.314
SS	18 (1.7)	1 (1.5)	0.033	0.984
T2DM	36 (3.4)	1 (1.5)	0.754	0.686
Hypertension	180 (17.0)	8 (11.9)	1.353	0.508
Cataract	31 (2.9)	1 (1.5)	0.498	0.780
Fracture	22 (2.1)	3 (4.5)	1.701	0.427
HBsAg+	24 (2.3)^a	5 (7.5)	6.814	0.033

黎族与汉族系统性红斑狼疮患者的主要临床特征

RICH HTML

PDF (PC)

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 20

相关文章 15

Metrics

本文评价

推荐阅读 0